Patricia A Ganz1, Laura Petersen2, Steven A Castellon2, Julienne E Bower2, Daniel H S Silverman2, Steven W Cole2, Michael R Irwin2, Thomas R Belin2. 1. Patricia A. Ganz, Thomas R. Belin, Fielding School of Public Health, University of California, Los Angeles; Patricia A. Ganz, Laura Petersen, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Patricia A. Ganz, Daniel H.S. Silverman, Steven W. Cole, Michael R. Irwin, David Geffen School of Medicine, University of California, Los Angeles; Steven A. Castellon, VA Greater Los Angeles Health Care System; Steven A. Castellon, Julienne E. Bower, University of California, Los Angeles; Julienne E. Bower, Steven W. Cole, Michael R. Irwin, Cousins Center for Psychoneuroimmunology, Semel Institute, University of California, Los Angeles, Los Angeles, CA. pganz@mednet.ucla.edu. 2. Patricia A. Ganz, Thomas R. Belin, Fielding School of Public Health, University of California, Los Angeles; Patricia A. Ganz, Laura Petersen, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Patricia A. Ganz, Daniel H.S. Silverman, Steven W. Cole, Michael R. Irwin, David Geffen School of Medicine, University of California, Los Angeles; Steven A. Castellon, VA Greater Los Angeles Health Care System; Steven A. Castellon, Julienne E. Bower, University of California, Los Angeles; Julienne E. Bower, Steven W. Cole, Michael R. Irwin, Cousins Center for Psychoneuroimmunology, Semel Institute, University of California, Los Angeles, Los Angeles, CA.
Abstract
PURPOSE: This report examines cognitive complaints and neuropsychological (NP) testing outcomes in patients with early-stage breast cancer after the initiation of endocrine therapy (ET) to determine whether this therapy plays any role in post-treatment cognitive complaints. PATIENTS AND METHODS: One hundred seventy-three participants from the Mind Body Study (MBS) observational cohort provided data from self-report questionnaires and NP testing obtained at enrollment (T1, before initiation of ET), and 6 months later (T2). Bivariate analyses compared demographic and treatment variables, cognitive complaints, depressive symptoms, quality of life, and NP functioning between those who received ET versus not. Multivariable linear regression models examined predictors of cognitive complaints at T2, including selected demographic variables, depressive symptoms, ET use, and other medical variables, along with NP domains that were identified in bivariate analyses. RESULTS: Seventy percent of the 173 MBS participants initiated ET, evenly distributed between tamoxifen or aromatase inhibitors. ET-treated participants reported significantly increased language and communication (LC) cognitive complaints at T2 (P = .003), but no significant differences in NP test performance. Multivariable regression on LC at T2 found higher LC complaints significantly associated with T1 LC score (P < .001), ET at T2 (P = .004), interaction between ET and past hormone therapy (HT) (P < .001), and diminished improvement in NP psychomotor function (P = .05). Depressive symptoms were not significant (P = .10). CONCLUSION: Higher LC complaints are significantly associated with ET 6 months after starting treatment and reflect diminished improvements in some NP tests. Past HT is a significant predictor of higher LC complaints after initiation of ET.
PURPOSE: This report examines cognitive complaints and neuropsychological (NP) testing outcomes in patients with early-stage breast cancer after the initiation of endocrine therapy (ET) to determine whether this therapy plays any role in post-treatment cognitive complaints. PATIENTS AND METHODS: One hundred seventy-three participants from the Mind Body Study (MBS) observational cohort provided data from self-report questionnaires and NP testing obtained at enrollment (T1, before initiation of ET), and 6 months later (T2). Bivariate analyses compared demographic and treatment variables, cognitive complaints, depressive symptoms, quality of life, and NP functioning between those who received ET versus not. Multivariable linear regression models examined predictors of cognitive complaints at T2, including selected demographic variables, depressive symptoms, ET use, and other medical variables, along with NP domains that were identified in bivariate analyses. RESULTS: Seventy percent of the 173 MBSparticipants initiated ET, evenly distributed between tamoxifen or aromatase inhibitors. ET-treated participants reported significantly increased language and communication (LC) cognitive complaints at T2 (P = .003), but no significant differences in NP test performance. Multivariable regression on LC at T2 found higher LC complaints significantly associated with T1 LC score (P < .001), ET at T2 (P = .004), interaction between ET and past hormone therapy (HT) (P < .001), and diminished improvement in NP psychomotor function (P = .05). Depressive symptoms were not significant (P = .10). CONCLUSION: Higher LC complaints are significantly associated with ET 6 months after starting treatment and reflect diminished improvements in some NP tests. Past HT is a significant predictor of higher LC complaints after initiation of ET.
Authors: Pauline M Maki; Ellen W Freeman; Gail A Greendale; Victor W Henderson; Paul A Newhouse; Peter J Schmidt; Nelda F Scott; Carol A Shively; Claudio N Soares Journal: Menopause Date: 2010-07 Impact factor: 2.953
Authors: Heather S L Jim; Kristin M Phillips; Sari Chait; Leigh Anne Faul; Mihaela A Popa; Yun-Hsiang Lee; Mallory G Hussin; Paul B Jacobsen; Brent J Small Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: Tim A Ahles; Andrew J Saykin; Brenna C McDonald; Yuelin Li; Charlotte T Furstenberg; Brett S Hanscom; Tamsin J Mulrooney; Gary N Schwartz; Peter A Kaufman Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: Jeanne S Mandelblatt; Arti Hurria; Brenna C McDonald; Andrew J Saykin; Robert A Stern; John W VanMeter; Meghan McGuckin; Tiffani Traina; Neelima Denduluri; Scott Turner; Darlene Howard; Paul B Jacobsen; Tim Ahles Journal: Semin Oncol Date: 2013-12 Impact factor: 4.929
Authors: Kevin T Liou; James C Root; Sheila N Garland; Jamie Green; Yuelin Li; Q Susan Li; Philip W Kantoff; Tim A Ahles; Jun J Mao Journal: Cancer Date: 2020-04-22 Impact factor: 6.860
Authors: M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Catherine M Bender; John D Merriman; Amanda L Gentry; Gretchen M Ahrendt; Sarah L Berga; Adam M Brufsky; Frances E Casillo; Meredith M Dailey; Kirk I Erickson; Frances M Kratofil; Priscilla F McAuliffe; Margaret Q Rosenzweig; Christopher M Ryan; Susan M Sereika Journal: Cancer Date: 2015-04-23 Impact factor: 6.860
Authors: Jamie S Myers; Theresa A Koleck; Susan M Sereika; Yvette P Conley; Catherine M Bender Journal: Support Care Cancer Date: 2017-03-01 Impact factor: 3.603
Authors: John D Merriman; Susan M Sereika; Adam M Brufsky; Priscilla F McAuliffe; Kandace P McGuire; Jamie S Myers; Mary L Phillips; Christopher M Ryan; Amanda L Gentry; Lindsay D Jones; Catherine M Bender Journal: Psychooncology Date: 2015-10-20 Impact factor: 3.894